Tilbury Douglas releases final flyover footage of its Medicines Manufacturing Innovation Centre (MMIC) in Scotland, as the project nears completion
The innovation centre, built by Tilbury Douglas, will help solve major pharmaceutical industry challenges and accelerate access to affordable medicines.
Located in Renfrewshire, at the heart of the emerging Advanced Manufacturing Innovation District Scotland (AMIDS), the £35m facility will develop next-generation pharmaceutical manufacturing processes to drive forward innovation in the medicines supply chain.
Pioneered through a public-private collaboration
The facility has been pioneered through a public-private collaboration between technology innovation organisation, CPI, the University of Strathclyde, UK Research and Innovation, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.
Two-storey steel frame construction
The centre, a two-storey steel frame construction on piled foundations, includes an office and reception area plus GMP compliant facilities. This includes four ISO 8 pharmaceutical cleanrooms with associated materials and people airlocks as well as GMP compliant supporting activities including warehousing, process utilities, QC and analytical labs.
In the first five years of its operation, the centre is expected to support over 100 jobs, both technical and non-technical, and generate £200M investment in advanced technologies.
International beacon in medicines manufacturing
The facility aims to become an international beacon in medicines manufacturing, driving international engagement and attracting firms that do not currently have a presence in the UK.
Dave Tudor, managing director of the Medicines Manufacturing Innovation Centre at CPI, said: “The Medicines Manufacturing Innovation Centre will help the pharmaceutical industry to increase momentum in technology translation by creating partnerships, working with regulators and partnering with innovators.
“This will ultimately lead to a reduction in time to market, drive productivity, improve compliance and reduce the carbon footprint of medicines manufacturing. We continue to collaborate with industry and academic partners to develop next-generation digital manufacturing technologies, bringing us closer to medicines innovation that will ultimately benefit patients.”
Watch the final flyover #video of our Medicines Manufacturing Innovation Centre in Renfrewshire.
With the project nearing completion, we look forward to our client CPI officially opening MMIC later in the year.
Watch it here: https://t.co/JvjWODRcXo#project #construction
— Tilbury Douglas (@Tilbury_douglas) July 21, 2022
Cameron Stewart, regional director at Tilbury Douglas, added: “We are delighted to be involved in a project that will make such a difference to the pharmaceutical industry.”
